A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients
treated with this strategy consisting of initial therapy with pertuzumab as a single agent
and then addition of erlotinib for those who have stable disease or progressive disease at
three months (Simon design).